Cardiac Assist Devices
|
|
- Caren Page
- 6 years ago
- Views:
Transcription
1 Cardiac Assist Devices Current and Pipeline Products GDME1006FPR / Published March 2013
2 1 Table of Contents 1 Table of Contents List of Tables List of Figures Introduction Catalyst Competitive Assessment Cardiac Assist Device Market, Comparison of Key Marketed Products Ventricular Assist Devices Market, Key Company Share Ventricular Assist Devices, Comparison based on Pump Technology Ventricular Assist Devices Overview First-Generation Devices Second-Generation Devices Third-Generation Devices Fourth-Generation Devices Fifth-Generation Devices Sixth-Generation Devices Seventh-Generation Devices Counterpulsation Devices Adult Primary Implant Breakdown Brand-Specific Training Extracorporeal Ventricular Assist Devices AB5000 (Abiomed, Inc.) CentriMag, PediMag (Thoratec) Delta-Stream DP3 Pump (Medos Medizintechnik AG) Excor (Berlin Heart) Page 2 GDME1006FPR / Published MAR 2013
3 3.5.5 PVAD (Thoratec) RotaFlow (Maquet Cardiovascular) Intracorporeal Ventricular Assist Devices DuraHeart (Terumo) EvaHeart (Sun Medical Technology Research Corporation) Heart Assist 5 (MicroMed Cardiovascular, Inc.) HeartMate II (Thoratec) HVAD (HeartWare) Incor (Berlin Heart) IVAD (Thoratec) Jarvik 2000 (Jarvik Heart) Percutaneous Ventricular Assist Devices Impella (Abiomed, Inc.) Synergy (CircuLite) TandemHeart (Cardiac Assist, Inc.) Intra-Aortic Balloon Pumps Overview AutoCAT 2 Wave (Teleflex) CardioSave (Maquet Cardiovascular) CS300 (Maquet Cardiovascular) ivac (PulseCath) Xemex (Zeon) Extra-Aortic Balloon Pumps C-Pulse (Sunshine Heart) Total Artificial Heart Overview AbioCor (Abiomed) SynCardia (SynCardia Systems, Inc.) Page 3 GDME1006FPR / Published MAR 2013
4 3.11 Extracorporeal Membrane Oxygenation Pipeline Products Overview Ventricular Assist Devices CorAide, DexAide (Teleflex) DuraHeart II (Terumo) HeartMate III (Thoratec) HeartMate X (Thoratec) MiFlow (HeartWare) MiTiHeart LVAD (Mohawk Innovative Technology, Inc.) MVAD (HeartWare) PediaFlow VAD (HeartWare) PediPump (Cleveland Clinic) Revolution (Vadovations, Inc.) s.pump (Medos Medizintechnik AG) Percutaneous Ventricular Assist Devices HeartMate PHP (Thoratec) Reitan Catheter Pump (CardioBridge GmbH) Total Artificial Hearts AbioCor II (Abiomed, Inc.) Carmat TAH (Carmat) Golding TAH (Cleveland Clinic) Beatless Heart (Texas Heart Institute) MagScrew (Cleveland Clinic) ReinHeart (University of Aachen) Other Current and Future Players Company Profiles Page 4 GDME1006FPR / Published MAR 2013
5 5.1.1 Abiomed, Inc Berlin Heart CardiacAssist, Inc CardioBridge Carmat CircuLite HeartWare International, Inc Jarvik Heart Maquet Cardiovascular Medos Medizintechnik AG MicroMed Cardiovascular, Inc MiTiHeart Corporation PulseCath BV Sunshine Heart SynCardia Systems, Inc Teleflex Medical Terumo Thoratec Sun Medical Zeon Medical Other Appendix Abbreviations Bibliography Methodology Forecasting Sources Used Forecast Assumptions and Methods Page 5 GDME1006FPR / Published MAR 2013
6 6.4 Coverage Secondary Research Forecasting Methodology Pricing Assumptions Physicians and Specialists Included in this Study Primary Research About the Authors Analysts Global Head of Healthcare Definitions About GlobalData Contact Us Disclaimer Page 6 GDME1006FPR / Published MAR 2013
7 1.1 List of Tables Table 1: Cardiac Assist Devices by Launch Table 2: Ventricular Assist Devices Market, Global, Company Share ($m), Table 3: Cardiac Assist Devices by Type Table 4: Product Profile AB Table 5: AB5000 SWOT Analysis, Table 6: Product Profile CentriMag, PediMag Table 7: CentriMag, PediMag SWOT Analysis, Table 8: Product Profile Delta-Stream DP3 Pump Table 9: Delta-Stream DP3 SWOT Analysis, Table 10: Product Profile Excor Table 11: Excor SWOT Analysis, Table 12: Product Profile PVAD Table 13: PVAD SWOT Analysis, Table 14: Product Profile RotaFlow Table 15: RotaFlow SWOT Analysis, Table 16: Product Profile DuraHeart Table 17: DuraHeart SWOT Analysis, Table 18: Product Profile EvaHeart Table 19: EvaHeart SWOT Analysis, Table 20: EvaHeart US Pivotal BTT Trial Table 21: Product Profile HeartAssist Table 22: HeartAssist 5 SWOT Analysis, Table 23: Product Profile HeartMate II Table 24: HeartMate II SWOT Analysis, Table 25: REVIVE-IT Table 26: ROADMAP Table 27: REMATCH Page 7 GDME1006FPR / Published MAR 2013
8 Table 28: Product Profile HVAD Table 29: HVAD SWOT Analysis, Table 30: ENDURANCE Table 31: ADVANCE Table 32: Product Profile Incor Table 33: Incor SWOT Analysis, Table 34: Product Profile IVAD Table 35: IVAD SWOT Analysis, Table 36: Product Profile Jarvik Table 37: Jarvik 2000 SWOT Analysis, Table 38: Jarvik 2000 US Pivotal DT Trial Table 39: Product Profile Impella Table 40: Impella SWOT Analysis, Table 41: Product Profile Synergy Table 42: Synergy SWOT Analysis, Table 43: Synergy CE Mark EU Trial Table 44: Product Profile TandemHeart Table 45: TandemHeart SWOT Analysis, Table 46: TandemHeart to Reduce Infarct Size (TRIS) Table 47: Product Profile AutoCAT 2 Wave Table 48: AutoCAT 2 SWOT Analysis, Table 49: Product Profile CardioSave Table 50: CardioSave SWOT Analysis, Table 51: Product Profile CS Table 52: CS300 SWOT Analysis, Table 53: Product Profile ivac Table 54: ivac SWOT Analysis, Table 55: Product Profile Xemex Page 8 GDME1006FPR / Published MAR 2013
9 Table 56: Xemex SWOT Analysis, Table 57: Comparing Leading CAD Products Table 58: Product Profile C-Pulse Table 59: C-Pulse SWOT Analysis, Table 60: C-Pulse US Pivotal Trial Table 61: Product Profile AbioCor Table 62: AbioCor SWOT Analysis, Table 63: Product Profile SynCardia Table 64: SynCardia SWOT Analysis, Table 65: Cardiac Assist Devices in Pipeline Table 66: Product Profile CorAide, DexAide Table 67: CorAide, DexAide SWOT Analysis, Table 68: Product Profile DuraHeart II Table 69: DuraHeart II SWOT Analysis, Table 70: Product Profile HeartMate III Table 71: HeartMate III SWOT Analysis, Table 72: Product Profile HeartMate X Table 73: HeartMate X SWOT Analysis, Table 74: Product Profile MiFlow Table 75: MiFlow SWOT Analysis, Table 76: Product Profile MiTiHeart Corporation Table 77: MiTiHeart SWOT Analysis, Table 78: Product Profile MVAD Table 79: MVAD SWOT Analysis, Table 80: Product Profile PediaFlow Table 81: PediaFlow SWOT Analysis, Table 82: Product Profile PediPump Table 83: PediPump SWOT Analysis, Page 9 GDME1006FPR / Published MAR 2013
10 Table 84: Product Profile Revolution Table 85: Revolution SWOT Analysis, Table 86: Product Profile s.pump Table 87: s.pump SWOT Analysis, Table 88: Product Profile HeartMate PHP Table 89: HeartMate PHP SWOT Analysis, Table 90: Product Profile Reitan Catheter Pump Table 91: Reitan Catheter Pump SWOT Analysis, Table 92: Product Profile AbioCor II Table 93: AbioCor II SWOT Analysis, Table 94: Product Profile Carmat Table 95: Carmat SWOT Analysis, Table 96: Product Profile Golding TAH Table 97: Golding TAH SWOT Analysis, Table 98: Product Profile Beatless Heart Table 99: Beatless Heart SWOT Analysis, Table 100: Product Profile MagScrew Table 101: MagScrew SWOT Analysis, Table 102: Product Profile ReinHeart Table 103: ReinHeart SWOT Analysis, Table 104: Company Profile Abiomed, Inc Table 105: Abiomed SWOT Analysis, Table 106: Company Profile Berlin Heart Table 107: Berlin Heart SWOT Analysis, Table 108: Company Profile Cardiac Assist Table 109: Cardiac Assist SWOT Analysis, Table 110: Company Profile - CardioBridge Table 111: CardioBridge SWOT Analysis, Page 10 GDME1006FPR / Published MAR 2013
11 Table 112: Company Profile - Carmat Table 113: Carmat SWOT Analysis, Table 114: Company Profile - CircuLite Table 115: CircuLite SWOT Analysis, Table 116: Company Profile HeartWare Table 117: HeartWare SWOT Analysis, Table 118: Company Profile Jarvik Heart Table 119: Jarvik Heart SWOT Analysis, Table 120: Company Profile Maquet Cardiovascular Table 121: Maquet Cardiovascular SWOT Analysis, Table 122: Company Profile Medos Medizintechnik AG Table 123: Medos Medizintechnik AG SWOT Analysis, Table 124: Company Profile MicroMed Cardiovascular, Inc Table 125: MicroMed Cardiovascular SWOT Analysis, Table 126: Company Profile MiTiHeart Corporation Table 127: MiTiHeart Corporation SWOT Analysis, Table 128: Company Profile PulseCath Table 129: PulseCath SWOT Analysis, Table 130: Company Profile Sunshine Heart Table 131: Sunshine Heart SWOT Analysis, Table 132: Company Profile SynCardia Systems Table 133: SynCardia Systems SWOT Analysis, Table 134: Company Profile - Teleflex Table 135: Teleflex SWOT Analysis, Table 136: Company Profile Terumo Heart Table 137: Terumo Heart SWOT Analysis, Table 138: Company Profile Thoratec Table 139: Thoratec SWOT Analysis, Page 11 GDME1006FPR / Published MAR 2013
12 Table 140: Company Profile Sun Medical Table 141: Sun Medical SWOT Analysis, Table 142: Company Profile Zeon Medical Table 143: Zeon Medical SWOT Analysis, Table 144: Sources of Epidemiological Data Used for the Forecast Table 145: New York Heart Association (NYHA) Class Distributions Description Page 12 GDME1006FPR / Published MAR 2013
13 1.2 List of Figures Figure 1: Ventricular Assist Devices Market, Global, Company Share (%), Page 13 GDME1006FPR / Published MAR 2013
14 Introduction 2 Introduction Cardiac Assist Devices (CAD) are mechanical pumps that work in conjunction with a patient s heart to improve the pumping efficiency, increase the cardiac output and restore normal blood circulation. The devices are typically employed in patients suffering from end-stage Congestive Heart Failure (CHF), where the chances of survival through oral medications alone become minimal. The scarcity of donor organs has led to the development of interim interventions that utilize CADs, which comprise three segments: Ventricular Assist Devices (VAD), Intra-Aortic Balloon Pumps (IABP), and Total Artificial Hearts (TAH). These mechanical pumps are typically used for short-term purposes, allowing the heart to rest long enough that it can recuperate and return to normal and independent function. This is especially helpful for treating postcardiotomy cardiogenic shock, as these devices can provide a Bridge-To- Transplantation (BTT) or Bridge-To-Recovery (BTR) option for patients with end-stage heart failure. CADs can also be used for long-term Destination Therapy (DT) treatments in patients who are not surgical candidates for transplant but have severe heart failure. As donor hearts can be extremely difficult to get, CADs offer an alternative option for patients with critical heart failure who are waiting to receive a donor heart. 2.1 Catalyst Significant limitations and unmet needs with heart transplantation have generated considerable, continued interest in the development of CADs that are capable of supporting patients with severe CHF, either until donor hearts become available or as an alternative to heart transplantation for long-term use. These CAD devices include Ventricular Assist Devices, Intra-Aortic Balloon Pumps, and Total Artificial Hearts. While heart transplantation remains the gold standard and preferred treatment option for patients with advanced Congestive Heart Failure (CHF), the number of transplant candidates far exceeds the donor pool. The International Society for Heart and Lung Transplantation Registry 2012 Report notes a worldwide continued decrease in the number of donor hearts available. Advanced CHF patients on inotropic support have a mortality rate of 50% at three months and 94% at one year; cardiac assist devices can support these end-stage patients with significantly better survival rates. Many heart failure patients are ineligible for transplant due to old age or comorbidities; approximately 50% of patients who need a transplant are disqualified due to age. Opportunistic infection, rejection, malignancy, and graft coronary artery disease continue to be limitations to heart transplantation. Page 14 GDME1006FPR / Published MAR 2013
15 Introduction It has been shown that implantation of a CAD earlier on during the CHF progression can significantly slow the worsening of the condition, and in some cases even reverse the process to improve patient condition. CADs can greatly improve organ function. Destination therapy or tandem therapy, with a CAD in combination with cell transplantation, genetic treatment, or drug therapy, may be an alternative option to circumvent the shortage of donor hearts worldwide. Page 15 GDME1006FPR / Published MAR 2013
16 Appendix 6.11 About GlobalData GlobalData is a leading global provider of business intelligence in the Healthcare industry. GlobalData provides its clients with up-to-date information and analysis on the latest developments in medical device research, disease analysis, and clinical research and development. Our integrated business intelligence solutions include a range of interactive online databases, analytical tools, reports and forecasts. Our analysis is supported by a 24/7 client support and analyst team. GlobalData has offices in New York, Boston, London, India and Singapore Disclaimer All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form by any means, electronic, mechanical, photocopying, recording or otherwise, without the prior permission of the publisher, GlobalData. Page 182 GDME1006FPR / Published MAR 2013
JPMorgan Healthcare Conference
JPMorgan Healthcare Conference Keith Grossman, Chief Executive Officer January 14, 2015 Disclosures Forward-Looking Statements This presentation includes forward-looking statements, including our current
More informationREFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1180DFR PUBLICATION DATE M AY 2013 STELARA (PSORIASIS) - Executive Summary Table below presents key metrics for Stelara in the seven of the nine major pharmaceutical markets. Stelara:
More informationGermany Tissue Engineered - Skin Substitutes Market Outlook to 2020
Germany Tissue Engineered - Skin Substitutes Market Outlook to 2020 Reference Code: GDMECC0884DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables...
More informationBrazil Gastric Balloon Procedures Outlook to 2020
Brazil Gastric Balloon Procedures Outlook to 2020 Reference Code: GDMECC0472PDB Publication Date: July 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of Figures...
More informationREFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - US Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in the US 2012 We estimate the 2012 PsO drug
More informationSAMPLE. Mexico Orthopedic Prosthetics Market Outlook to Reference Code: GDMECC0156DB. Publication Date: February 2014
Mexico Orthopedic Prosthetics Market Outlook to 2020 Reference Code: GDMECC0156DB Publication Date: February 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationFrance Pressure Relief Devices Market Outlook to 2020
France Pressure Relief Devices Market Outlook to 2020 Reference Code: GDMECC0869DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 3 1.2 List of
More informationREFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Ulcerative Colitis in the United States In 2012,
More informationBRIC Surgical Sutures Market Outlook to 2020
BRIC Surgical Sutures Market Outlook to 2020 Reference Code: GDMECR0270DB Publication Date: October 2014 Page 1 1 Table of Contents 1 Table of Contents... 2 1.1 List of Tables... 5 1.2 List of Figures...
More informationREFERENCE CODE GDME0205M AR PUBLICATION DATE MARCH 2014 ELECTROPHYSIOLOGY - GLOBAL ANALYSIS AND MARKET FORECASTS
REFERENCE CODE GDME0205M AR PUBLICATION DATE MARCH 2014 ELECTROPHYSIOLOGY - Executive Summary Electrophysiology: Key Metrics in 10 Major Markets Atrial flutter (AFL) prevalence, 2013 484,893 Wolff-Parkinson-White
More informationRobocop and his Artificial Heart
Robocop and his Artificial Heart Abstract Artificial Hearts are a blend between mechanical, electronics and software engineering and also rely on the latest findings of medicine. They have been the dream
More informationSAMPLE. Bracco Imaging S.p.A.Market Share Analysis. Bracco Imaging S.p.A. Market Share Analysis GDME0639CDB / Published January 2013
Market Share Analysis Reference Code: GDME0639CDB Publication Date: January 2013 GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold in any form Page 1 Table
More informationREFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023
REFERENCE CODE GDHC266CFR PUBLICAT ION DATE DECEMBER 2014 RHEUMATOID ARTHRITIS JAPAN DRUG FORECAST AND MARKET ANALYSIS TO 2023 Executive Summary Sales for Rheumatoid Arthritis in Japan The Rheumatoid Arthritis
More informationREFERENCE CODE GDME1016FPR PUBLICATION DATE JULY 2013 HERNIA REPAIR CURRENT AND FUTURE PLAYERS
REFERENCE CODE GDME1016FPR PUBLICATION DATE JULY 2013 HERNIA REPAIR 1 1... 2 1.1 List of Tables... 7 1.2 List of Figures... 11 2 Introduction... 14 2.1 Catalyst... 15 3 Competitive Assessment... 16 3.1
More informationKeeping Patients and Medical Professionals at the Center of Everything We Do
Keeping Patients and Medical Professionals at the Center of Everything We Do To fulfill its corporate mission of Contributing to Society through Healthcare, Terumo continually rises to the challenge of
More informationHemophilia A and B Recombinant Factor Replacement Therapy - 5EU Drug Forecast and Market Analysis to 2024
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Hemophilia A and B Recombinant Factor Replacement Therapy - 5EU Drug Forecast and Market Analysis to 2024 Hemophilia
More informationMEDICAL DEVICES : Guidance document
EUROPEAN COMMISSION DG ENTERPRISE Directorate G Unit 4 - Pressure Equipment, Medical Devices, Metrology MEDICAL DEVICES : Guidance document MEDDEV 2. 1/2 rev 2 26 April 1994 GUIDELINES RELATING TO THE
More informationBiomedical Engineering, Biostatistics and Epidemiology at Stellenbosch University Prof Martin Nieuwoudt
Biomedical Engineering, Biostatistics and Epidemiology at Stellenbosch University Prof Martin Nieuwoudt DST/NRF Centre of Excellence in Epidemiological Modelling and Analysis (SACEMA) and Biomedical Engineering,
More informationCardinal Health, Inc. (CAH) - Financial and Strategic SWOT Analysis Review
Cardinal Health, Inc. (CAH) - Financial and Strategic SWOT Analysis Review Cardinal Health, Inc. (CAH) - Financial and Strategic SWOT Analysis Review Sector Publishing Intelligence Limited (SPi) has been
More informationHemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market Analysis to 2024
Hemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market Analysis to 2024 Hemophilia A and B Recombinant Factor Replacement Therapy - Argentina Drug Forecast and Market
More informationSupporting medical technology development with the analytic hierarchy process Hummel, Janna Marchien
University of Groningen Supporting medical technology development with the analytic hierarchy process Hummel, Janna Marchien IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationTodays Agenda. Class progress so far Business plan basics
Todays Agenda Class progress so far Business plan basics Class Progress So Far Idea generation Market Research Prototyping Class Questions What is a Business Plan? Why Write A Business Plan? What Should
More informationMEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS
MEDICAL DEVICES: TECHNOLOGIES AND GLOBAL MARKETS HLC170B January 2017 Vijay Laxmi Project Analyst ISBN: 1-62296-410-1 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215 (toll-free
More informationSanten Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device
Santen Acquisition of InnFocus, Developer of MicroShunt Glaucoma Implant Device Akira Kurokawa President & CEO August 2, 2016 Copyright 2016 Santen Pharmaceutical Co., Ltd. All rights reserved. 1 External
More informationAMERICAN HEART ASSOCIATION RESEARCH FACTS FY
AMERICAN HEART ASSOCIATION RESEARCH FACTS FY 2016-2017 LIFE IS WHY. RESEARCH IS HOW. The AHA research program has tremendous impact on science discovery and researchers careers. New knowledge that results
More informationMechanical Engineer. If interested, please submit your resumes to
The Foundry is the premier medical device company incubator for inventors to rapidly transform their concepts into companies. The Foundry team has founded and financed ten medical device companies since
More informationThe Leader in the Science of Heart Valves and Hemodynamic Monitoring
The Leader in the Science of Heart Valves and Hemodynamic Monitoring Cautionary Statement Presentations and comments made today by the management of Edwards Lifesciences Corporation will include forward
More informationClinical Commissioning Policy: Eculizumab for the treatment of refractory antibody mediated rejection post kidney transplant
Clinical Commissioning Policy: Eculizumab for the treatment of refractory antibody mediated rejection post kidney transplant January 2014 Reference: NHS ENGLAND A07/P/c NHS England Clinical Commissioning
More informationREFERENCE CODE GDME1123CFR PUBLICAT ION DATE DECEMBER 2014 MAGNETIC RESONANCE IMAGING SYSTEMS APAC ANALYSIS AND MARKET FORECASTS
REFERENCE CODE GDME1123CFR PUBLICAT ION DATE DECEMBER 2014 MAGNETIC RESONANCE IMAGING SYSTEMS Executive Summary Magnetic Resonance Imaging Key Metrics: Key Events and Pipeline Assessment 2013 Market Sales
More informationCIBA Vision Corporation Market Share Analysis
CIBA Vision Corporation Market Share Analysis Reference Code: GDME0740CDB Publication Date: January 2013 GlobalData. This report is a licensed product and is not to be copied, reproduced, shared or resold
More informationREFERENCE CODE GDHC54PIDR PUBLICATION DATE JULY 2013 POSTMENOPAUSAL VAGINAL ATROPHY - GLOBAL DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC54PIDR PUBLICATION DATE JULY 2013 POSTMENOPAUSAL VAGINAL ATROPHY - Executive Summary Postmenopausal Vaginal Atrophy: Key Metrics in the Seven Major Pharmaceutical Markets 2012 Epidemiology
More informationShaping the Future of Biomedical Device Design and Diagnostics. Kristian Debus
Shaping the Future of Biomedical Device Design and Diagnostics Kristian Debus Overview Biomedical Device Design: Benchtop and Clinical Trial Support Simulation and the regulatory system ASME V&V 40, MDDT,
More informationAnalytics. HealthView. Cardiovascular Data Intelligence.
HealthView Analytics Cardiovascular Data Intelligence www.lumedx.com info@lumedx.com Meaningful Data for Clinical and Operational Success Cardiovascular service lines are under tremendous pressure to perform
More informationBiomedical sensor technology: state - of the art and future roadmap
Biomedical sensor technology: state - of the art and future roadmap Ralph W. Bernstein SINTEF Microsystems and nanotechnology 1 MiNaLab Clean room area: SINTEF: 800 m 2 University of Oslo: 600 m 2 Micro
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationICT investment trends in South Africa
ICT investment trends in South Africa Enterprise ICT spending patterns through to the end of 2016 September 2015 KG0177CI Single User Price: US$2995 Introduction Summary Kable s survey of South African
More informationCurrent Trends at FDA: Implications for Data Requirements
Introduction The environment surrounding medical device regulation in the United States has always been rigorous, but recent events including well-publicized quality issues associated with implantable
More informationADDIS ABABA UNIVERSITY CENTER OF BIOMEDICAL ENGINEERING
ADDIS ABABA UNIVERSITY CENTER OF BIOMEDICAL ENGINEERING November 2013 History of Biomedical Engineering Definition of Biomedical Engineering Achievements of Biomedical Engineering Streams in Biomedical
More informationTestimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association
Testimony of Christopher Newton-Cheh, MD, MPH Volunteer for the American Heart Association Before the House Energy and Commerce Subcommittee on Health 21st Century Cures: Examining the Regulation of Laboratory
More informationHealthcare Payers: In Pursuit of Four Digital Objectives
White paper Healthcare Payers: In Pursuit of Four Digital Objectives Manoj Narayan Abstract Today, the healthcare industry is undergoing a significant change. Consumers are technologically savvy and expect
More informationMapping the Patient Journey: Harnessing the power of big data and analytics A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A S G ES data and analytics A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced
More informationTerumo Corporation ANNUAL REPORT 2017
Terumo Corporation ANNUAL REPORT 2017 Keeping Patients and Medical Professionals at the Center of Everything We Do To fulfill its corporate mission of Contributing to Society through Healthcare, Terumo
More informationThe Southeast Asian Polyolefin Industry Set to Emerge as a Key Market with Growing Demand and Capacity Additions. GDCH009TR / Published April 2013
The Southeast Asian Polyolefin Industry Set to Emerge as a Key Market with Growing Demand and Capacity Additions GDCH009TR / Published April 2013 Thailand is the Leading Player in the Southeast Asian Polyolefin
More informationCellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Cellular Tumor Antigen P53 (Tumor Suppressor P53 or Antigen NY-CO-13) - Pipeline Review, H1 2016 Cellular Tumor
More informationRWE from pre-clinical to launch. RWE from pre-clinical to launch. Standard of care Unmet needs. Disease burden Budget impact.
Real Real World World Data Data Across Across the the Product Product Lifecycle: Lifecycle: RWE from pre-clinical to launch RWE from pre-clinical to launch Standard of care Unmet needs Disease burden Budget
More informationHOW TO APPLY FOR MEDICAL DEVICE REGISTRATION UNDER MEDICAL DEVICE ACT 2012 (ACT 737)
MDA/GL No 1: July 2013 Guidelines for implementation of medical device regulatory system HOW TO APPLY FOR MEDICAL DEVICE REGISTRATION UNDER MEDICAL DEVICE ACT 2012 (ACT 737) [Appendix 4 Schedule 3 Medical
More informationPublished on Market Research Reports Inc. (https://www.marketresearchreports.com)
Published on Market Research Reports Inc. (https://www.marketresearchreports.com) Home > Hydropower in Norway, Market Outlook to 2030, Update 2016 - Capacity, Generation, Levelized Cost of Energy (LCOE),
More informationThree-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G.
Three-Year Clinical Outcomes with Everolimus-Eluting Bioresorbable Scaffolds: Results from the Randomized ABSORB III Trial Stephen G. Ellis MD Dean J. Kereiakes MD and Gregg W. Stone MD for the ABSORB
More informationThe Future of Market Access A FirstWord ExpertViews Dossier Report
AM PL E PA G ES S A G ES S A FirstWord ExpertViews Dossier Report Published Copyright 2016 Doctor s Guide Publishing Limited All rights reserved. No part of this publication may be reproduced or used in
More informationReimagining Life Sciences With AI-Enabled Digital Transformation. Abstract
Reimagining Life Sciences With AI-Enabled Digital Transformation Abstract Technological, regulatory and environmental changes, along with an increasingly active involvement of patients in their treatment
More informationOpportunities in the Health Care Practice at Analysis Group
Opportunities in the Health Care Practice at Analysis Group Johns Hopkins Blomberg School of Public Health October 3, 2016 You Will Learn Today: Who the Analysis Group is What our Health Care Practice
More informationPost-1945 Developments: New technology and bioethics
Post-1945 Developments: Post-1945 Developments: Kidney dialysis Ventilator Heart-lung machine 1 Post-1945 Developments: kidney dialysis 1921 saw the first attempts to clear the blood of impurities externally
More informationStericycle, Inc. (SRCL) - Financial and Strategic SWOT Analysis Review
Stericycle, Inc. (SRCL) - Financial and Strategic SWOT Analysis Review Stericycle, Inc. (SRCL) - Financial and Strategic SWOT Analysis Review Sector Publishing Intelligence Limited (SPi) has been marketing
More informationOPERATOR APPROACHES TO IoT: FROM CONNECTIVITY TO PLATFORMS AND FULL SOLUTIONS
analysysmason.com RESEARCH STRATEGY REPORT OPERATOR APPROACHES TO IoT: FROM CONNECTIVITY TO PLATFORMS AND FULL SOLUTIONS TOM REBBECK Analysys Mason Limited 2016 About this report This report analyses the
More informationGlobal Transcatheter Aortic Valve Replacement (TAVR) Market Report
Global Transcatheter Aortic Valve Replacement (TAVR) Market Report ----------------------------------------- 2013 Executive Summary The Transcatheter Aortic Valve Replacement (TAVR) is a relatively new
More informationDOCUMENT DESPATCH ADVICE DRAFT IN WIDE CIRCULATION MHR 06 /T- 50/51/52/53/ TECHNICAL COMMITTEE: MHR 06
DRAFT IN WIDE CIRCULATION TECHNICAL COMMITTEE: MHR 06 DOCUMENT DESPATCH ADVICE Ref Date MHR 06 /T- 50/51/52/53/54 09-05-2008 DOC NO: MHR 06 (0114)/ISO 7199:1996 TITLE Cardiovascular implants and artificial
More informationSurface Characterization of Biomaterials
Surface Characterization of Biomaterials Biomaterials are determined The desire for well-being and long life expectancy goes hand in-hand with the use of non-viable materials to conserve health. 2000 years
More informationShivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare
Shivom, the global Genomics-Blockchain Ecosystem The Next Era of Genomics and Healthcare The world of healthcare is changing - with two revolutionary technologies, genomics and blockchain poised to significantly
More informationBioabsorbable metal stents: properties, modeling and open questions
Biomedical Engineering Bioabsorbable metal stents: properties, modeling and open questions Palma Tartaglione Supervisor: Prof. Ferdinando Auricchio Co-supervisor : Ing. Mauro Ferraro December 16, 2014
More informationMRI Systems Market to 2018
MRI Systems Market to 2018 Technological advancements, Increasing Number of Applications and Advent of MRI Compatible Pacemakers to Drive Future Growth GBI Research Report Guidance GBI Research Report
More informationA Coordinated Registry Network Based on the Vascular Quality Initiative: VISION. Vascular Implant Surveillance & Interventional Outcomes Network
A Coordinated Registry Network Based on the Vascular Quality Initiative: VISION Vascular Implant Surveillance & Interventional Outcomes Network Jack L. Cronenwett, MD Medical Director, Society for Vascular
More informationICT investment trends in Ireland Enterprise ICT spending patterns through to the end of 2016
ICT investment trends in Ireland Enterprise ICT spending patterns through to the end of 2016 August 2015 KG0176CI Single User Price: US$2995 Introduction Summary The Irish economy s return to growth, driven
More informationNew Hearts for Old The Story of Transplantation. Changes in view of human body
New Hearts for Old The Story of Transplantation Changes in view of human body 12th century anatomy manuscript Illustration for potential donors 1 History of Transplantation & Transfusion 1800 1900 1950
More informationISO INTERNATIONAL STANDARD. Implants for surgery Active implantable medical devices Part 4: Implantable infusion pumps
INTERNATIONAL STANDARD ISO 14708-4 First edition 2008-11-15 Implants for surgery Active implantable medical devices Part 4: Implantable infusion pumps Implants chirurgicaux Dispositifs médicaux implantables
More informationThe Regulatory Imperative The impact on practice of lung transplantation
The Regulatory Imperative The impact on practice of lung transplantation Christopher Wigfield, MD MD FRCS(C/Th) Associate Professor of Surgery Surgical Director, Lung Transplant Program The Regulatory
More informationDisclaimer This presentation expresses my personal views on this topic and must not be interpreted as the regulatory views or the policy of the FDA
On multiplicity problems related to multiple endpoints of controlled clinical trials Mohammad F. Huque, Ph.D. Div of Biometrics IV, Office of Biostatistics OTS, CDER/FDA JSM, Vancouver, August 2010 Disclaimer
More informationHow Information Transformation Drives Healthcare Performance
perspective How Information Transformation Drives Healthcare Performance Abstract Healthcare delivery in the US is experiencing tectonic change and has rapidly moved towards a Consumer-centric, market-driven
More informationREFERENCE CODE GDPE0683ICR PUBLICATION DATE AUGUST 2013 PERU POWER MARKET OUTLOOK TO MARKET TRENDS, REGULATIONS AND COMPETITIVE LANDSCAPE
REFERENCE CODE GDPE0683ICR PUBLICATION DATE AUGUST 2013 PERU POWER MARKET OUTLOOK TO 2030 - Executive Summary Thermal Capacity Dominates Power Mix Power generation capacity in Peru is currently dominated
More informationISO INTERNATIONAL STANDARD. Needle-free injectors for medical use Requirements and test methods
INTERNATIONAL STANDARD ISO 21649 First edition 2006-06-01 Needle-free injectors for medical use Requirements and test methods Injecteurs sans aiguille à usage médical Exigences et méthodes d'essai Reference
More informationYASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.
YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN
More informationOff Label or On Target? The Ethics of Investigational and Compassionate Uses
Off Label or On Target? The Ethics of Investigational and Compassionate Uses G. Kevin Donovan, MD, MA Director, Pellegrino Center for Clinical Bioethics Professor of Pediatrics Georgetown University School
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationStem Cells Canadian Perspective
Stem Cells Canadian Perspective John Laffey Critical Illness and Injury Research Centre, Keenan Research Centre, St Michael s Hospital. Departments of Anesthesia, Physiology and Interdepartmental Division
More informationProtocol. This trial protocol has been provided by the authors to give readers additional information about their work.
Protocol This trial protocol has been provided by the authors to give readers additional information about their work. Protocol for: Resnic FS, Majithia A, Marinac Dabic D, et al. Registry-based prospective,
More informationOptimize efficiency with a universal system.
wins www.siemens.com/artis-one Optimize efficiency with a universal system.. Designed around you. Answers for life. Consistently efficient. Improve your competitiveness by mastering the balancing act between
More informationInsight to Gene Techno Science Co.,Ltd
Unlimited drug discovery from the beginning Ticker symbol: 4584 Insight to Gene Techno Science Co.,Ltd November 2017 2 Corporate Overview Chief Executive Founded March 2001 Masaharu Tani, President Listed
More informationIntroduction. This booklet also highlights ways to minimise the potential risks associated with micafungin use.
1 2 Introduction This booklet for prescribers and nurses provides practical guidance on the safe use and administration of micafungin, an echinocandin antifungal drug. This booklet also highlights ways
More informationFor personal use only
1047 Elwell Court, Palo Alto CA 94303 USA Tel (US): +1 (650) 390 9000 Tel (AU): 1-800-778-662 Fax: +1 650 390 9007 www.airxpanders.com ASX ANNOUNCEMENT AirXpanders issues Shareholder Newsletter PALO ALTO,
More informationFour entry strategies for small and midsized companies
White paper >7,100 sales reps >220 product launches in 20 countries supported since 2009 Emerging markets: Four entry strategies for small and midsized companies Executive summary Emerging markets offer
More informationProtect the Neck. Lieven Maene, MD. Marc Bosiers Koen Deloose Joren Callaert. Patrick Peeters Jürgen Verbist. Lieven Maene Roel Beelen.
A.Z. Sint-Blasius, Dendermonde Marc Bosiers Koen Deloose Joren Callaert Imelda Hospital, Bonheiden Protect the Neck Patrick Peeters Jürgen Verbist OLV Hospital, Aalst Lieven Maene Roel Beelen R.Z. Heilig
More informationDes cellules-souches dans le poumon : pourquoi faire?
Des cellules-souches dans le poumon : pourquoi faire? Karl-Heinz Krause Dept. of Pathology and Immunology, Medical Faculty Dept. of Genetic and Laboratory Medicine, University Hospitals Geneva, Switzerland
More informationBRILLIANCE II: Achieving Impact Through Licensing
The first baby treated by D- Rev s Brilliance device in Ogbomoso, Nigeria Photo: D- Rev BRILLIANCE II: Achieving Impact Through Licensing D- REV, STANFORD, CALIFORNIA ESTABLISHED 2007 KRISTA DONALDSON,
More informationDevelopment of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach
3 July 2017 EMA/CAT/216556/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the
More informationThe 3Rs: are Human Stem Cells and Organs on Chip alternatives?
The 3Rs: are Human Stem Cells and Organs on Chip alternatives? Towards precision medicine in future healthcare Christine Mummery Leiden University Medical Centre University Twente hdmt Three kinds of human
More informationMOBILE OPERATING TABLE BETACLASSIC
MOBILE OPERATING TABLE BETACLASSIC This document is intended to provide information to an international audience outside of the US. The Gold Standard Surgical Workplaces BETACLASSIC 3 BETACLASSIC ECONOMIC
More informationCurrent from currents
Current from currents (in main text) The use of large, efficient wind turbines to generate electrical power is becoming more commonplace throughout the world. Wind farms containing numerous turbines located
More informationFast Trak Services: a collaborative project to accelerate downstream biosimilar process development
GE Healthcare Fast Trak Services: a collaborative project to accelerate downstream biosimilar process development A case study Case study, 2924332 AA Fast Trak Services A collaborative project to accelerate
More informationExecutive Summary: Energy Efficiency Retrofits for Commercial and Public Buildings
RESEARCH REPORT Executive Summary: Energy Efficiency Retrofits for Commercial and Public Buildings HVAC, Lighting, Building Controls, Water Efficiency, Water Heating, Building Envelope, Energy Production,
More informationSystems & Biomedical Engineering Department. Systems and Biomedical Engineering Department Faculty of Engineering Cairo University
Systems & Biomedical Engineering Department Agenda Students' Mindsets and Careers Biomedical Engineering Biomedical Engineering Careers in Egypt Non-Biomedical Careers in Egypt Courses Agenda Students'
More informationAI FOR HEALTHCARE: BALANCING EFFICIENCY AND ETHICS.
AI FOR HEALTHCARE: BALANCING EFFICIENCY AND ETHICS www.infosys.com/aimaturity It will greatly benefit society to maintain an open mind about how decision-makers in healthcare organizations can work alongside
More informationMOSAIQUES DIAGNOSTICS
MOSAIQUES DIAGNOSTICS CLINICAL PROTEOMICS IN DRUG DEVELOPMENT INFORMATION Clinical Proteomics for early and differential diagnosis FDA Letter of Support Possibilities of a companion test in Drug Development
More informationChapter Two. Company and Marketing Strategy Partnering to Build Customer Relationships. i t s good and good for you 2-1
i t s good and good for you Chapter Two Company and Marketing Strategy Partnering to Build Customer Relationships 2-1 Company and Marketing Strategy Topic Outline Companywide Strategic Planning: Defining
More informationColgate-Palmolive (India) Ltd (COLPAL) - Financial and Strategic SWOT Analysis Review
Colgate-Palmolive (India) Ltd (COLPAL) - Financial and Strategic SWOT Analysis Review Colgate-Palmolive (India) Ltd (COLPAL) - Financial and Strategic SWOT Analysis Review Sector Publishing Intelligence
More informationHeparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Heparin Induced Thrombocytopenia. Temporal Aspects.
Heparin Induced Eric Kraut, MD Professor of Internal Medicine The Ohio State University Medical Center Heparin Induced Heparin induced thrombocytopenia occurs in up to 5 % of patients receiving unfractionated
More information